RxDoctor Payments Data

Brenna Sweeney

Women's Health · Barboursville, WVNPI 1427568831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 24.5% of the total. Reporting peaked in 2021 at $533 and has fallen 62.9% since, to $198 in 2025. Among women's health clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,354in general payments, 2019–2025

Across 52 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$331
  • Organon$190
  • Sage Therapeutics, LLC$159
  • AbbVie$150
  • Bayer$136
  • Pfizer$107
  • plus $280 from 8 others

What the payments were for

  • Food & beverage$1,354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,354 in reported general payments places this provider in the 95th percentile of 21 women's health providers in West Virginia.

See all women's health providers in West Virginia

Medicare billing

Part B allowed, 2024
$1,673
Medicare patients
28
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$5,698
Estradiol31$3,340
Fluconazole11$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$90$5,69813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 women's health providers in West Virginia.

Other women's health in Barboursville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →